Search Results

Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, announced the launch of Cyto-Cellect®PLUS.

Sphere Fluidics announced the appointment of Dale Levitzke as CEO with immediate effect, as Dr. Frank F. Craig, current CEO and co-founder, announces his retirement.

Sphere Fluidics announced the Cyto-Mine® platform has been selected by FairJourney Biologics, a world leading end-to-end antibody partner, providing integrated services across antibody discovery, engineering, and production, to expand its cell line development capabilities.

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced that it has appointed Kenneth Hitchner, BA MBA, as Chairman of its Board of Directors.

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced the introduction of new branding to align with its ambitious global commercial growth strategy.

Sphere Fluidics announced that it has appointed Richard Hammond as Chief Technical Officer.

Sphere Fluidics announced its involvement in 3DSecret, a four-year research project funded through the European Innovation Council’s Pathfinder Open 2022, established under Horizon Europe, the EU’s key funding program for research and innovation.

Medtronic plc, a global leader in healthcare technology, announced positive results demonstrating excellent safety and efficacy of the Affera™ Mapping and Ablation System with Sphere-9™ Catheter, an all-in-one pulsed field and radiofrequency ablation and high density mapping catheter for the treatment of persistent atrial fibrillation.

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced that it has opened a new state-of-the-art facility in Granta Park, Cambridgeshire, UK, to support the Company’s growth.